Non-small cell lung cancer metastatic Trials in Madrid, Spain
Conditions / Non-small cell lung cancer metastatic / Madrid, Spain
Non-small cell lung cancer metastatic has been the subject of sustained clinical investigation across multiple research sites.
17 total trials for this combination
Showing top 10 of 17 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | TERMINATED | PHASE3 |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer | TERMINATED | PHASE2/PHASE3 |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | TERMINATED | PHASE1/PHASE2 |
| NCT04619004 | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07144280 | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT01999673 | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer | COMPLETED | PHASE3 |
| NCT07144280 | A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | RECRUITING | — |
| NCT04154956 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03123783 | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | COMPLETED | PHASE1/PHASE2 |